About
Medyria is a Swiss MedTech start-up founded in 2013 by Dr. Mauro Sette. The company specializes in innovative cardiovascular medical technologies aimed at enhancing patient and physician safety while simplifying procedures and reducing costs. Headquartered in Technopark Winterthur, Switzerland, Medyria has facilities for administration, quality control, production, and research and development. The company's core technology focuses on blood flow velocity (BFV) sensing, which allows for real-time assessment of heart function during interventional cardiology procedures. Their flagship product, the PyCath, is a microcatheter that integrates BFV measurement, improving diagnostic accuracy and patient eligibility for treatment in angina pectoris cases. Medyria also supplies its BFV sensing technology to other manufacturers through an OEM business model, supporting innovation in cardiovascular diagnostics. With a strong intellectual property portfolio and successful funding rounds, Medyria is dedicated to advancing its technologies for better patient outcomes in cardiovascular care.
Technologies
Keywords
Company Information
- Employees13
- Founded2014
- Total Funding$12204720
Location
2 Technoparkstrasse, Winterthur, Zurich, Switzerland, 8406
